Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

SSRI

Therapeutic area intelligence for SSRI with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 3

Companies

Aurobindo Pharma →

Heritage Pharma →

Assets

Recent signals(7)

RegulatoryAugust 16, 2026

Aurobindo Pharma receives AP status for Paroxetine Hydrochloride supplement

Aurobindo Pharma USA has received an Abbreviated New Drug Application (ANDA) approval status for a supplement related to Paroxetine Hydrochloride.

StrategyAugust 16, 2026

Aurobindo Pharma's Paroxetine Hydrochloride ANDA091427 Receives AP Status

Aurobindo Pharma USA's ANDA091427 for Paroxetine Hydrochloride has received Abbreviated Approval (AP) status from the FDA.

RegulatoryAugust 2, 2026

FDA Accepts Application for Fluvoxamine Maleate by APPCO

The FDA has accepted the application ANDA220328 for Fluvoxamine Maleate submitted by APPCO.

StrategyJuly 25, 2026

FDA Grants Approval for Fluvoxamine Maleate ANDA220447 by Zydus Pharms

The FDA has granted approval for ANDA220447, a generic version of Fluvoxamine Maleate, submitted by Zydus Pharms.

StrategyJuly 13, 2026

Heritage Pharma's Sertraline Hydrochloride ANDA Submission Receives AP Status

Heritage Pharma's ANDA for Sertraline Hydrochloride has been granted Abbreviated Approval (AP) status.

RegulatoryJuly 11, 2026

FDA Accepts ANDA for Fluvoxamine Maleate by APPCO

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Fluvoxamine Maleate submitted by APPCO.

RegulatoryJune 27, 2026

FDA Approves ANDA220768 for Fluvoxamine Maleate by Micro Labs

The FDA has approved the Abbreviated New Drug Application (ANDA220768) for Fluvoxamine Maleate submitted by Micro Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.